(HealthDay)—The risk of acute graft-versus-host disease (GVHD) in hematopoietic stem cell transplantation with HLA-DPB1 mismatching is influenced by the HLA-DPB1 rs9277534 expression marker, according to a study published ...
Aug 14, 2015
0
12
Johns Hopkins and other cancer researchers report that a very short course of a chemotherapy drug, called cyclophosphamide, not only can prevent a life-threatening immune response in some bone marrow transplant recipients, ...
Oct 8, 2014
0
0
When a research team in China evaluated the efficacy and safety of using mesenchymal stem cells (MSCs) expanded from the bone marrow of non-self-donors to treat patients experiencing poor graft function (PGF) after receiving ...
Mar 18, 2013
0
1
An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of ...
Dec 10, 2012
0
0
A team of scientists led by a bone marrow transplant researcher at Fred Hutchinson Cancer Research Center has shed new light on why most bone marrow transplant patients who receive tissue-matched cells from unrelated donors ...
Sep 4, 2012
0
0
Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug ...
Jun 26, 2012
0
0
